Search Results | MSF Science Portal

Journal Article

|

Research

Khan U, Rich M, Franke M, Lachenal N, Ahmed S, et al.

2024-12-10 • Clinical Infectious Diseases

BACKGROUND

The 2022 WHO guidelines on multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) recommend six months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen ...

Journal Article

|

Research

Zeng C, Hernán MA, Trevisi L, Sauer S, Mitnick CD, et al.

2024-01-20 • medRxiv

RATIONALE

Treatment outcomes may be compromised among patients with multidrug- or rifampicin-resistant tuberculosis with additional fluoroquinolone resis...

Journal Article

|

Research

Huerga H, Khan UT, Bastard M, Mitnick CD, Lachenal N, et al.

2022-10-15 • Clinical Infectious Diseases

BACKGROUND
Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-ben...

Journal Article

|

Research

Hewison CCH, Khan UT, Bastard M, Lachenal N, Coutisson S, et al.

2022-09-15 • Clinical Infectious Diseases

RATIONALE
Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an obstacle to treatment completion.

OBJECTIVES
Evaluate safety of longer MDR/RR-TB...

Science Portal

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country MDR/RR-TB cohort

Effectiveness of a bedaquiline, linezolid, clofazimine “core” for multidrug-resistant tuberculosis

Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid and other second-line drugs

Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort